Pharma Market Intelligence
Transform the way you do business with intelligence that empowers you to make smarter commercial decisions in less time, helping you achieve accelerated growth in the pharmaceutical market.
Transform the way you do business with intelligence that empowers you to make smarter commercial decisions in less time, helping you achieve accelerated growth in the pharmaceutical market.
The full Scrip Asia 100 report includes:
• Common themes throughout the region
• Top 100 Pharma Companies including sales figures
• Top 20 companies by region
• Fastest growing and shrinking companies
• Innovation models and strategies being used
The Market Analysis tool helps you to pull together competitive analysis by locating and exporting the vital data you need, with minimal time and effort. Covering hundreds of device and diagnostic product types, the Market Analysis tool empowers you to quickly find and export the critical information you need, like:
Informatics Solutions
Streamline your workflow with a new solution that delivers critical disease overviews back to you quickly, easily, and efficiently with the new Pharma360.
Topic Diseases
Get the big picture trends and key takeaways with Citeline’s infographic, 2019 Completed Trials: The Beat Goes on for Industry Sponsored Trial Activity. Using pivotal data from Sitetrove, Trialtrove and Pharmaprojects, our graphic analysis covers the major industry clinical developments as only Citeline can.
Tap into expert analysis of the trends and what they mean for the future of pharma with Citeline’s latest whitepaper, 2019 Completed Trials: The Beat Goes on for Industry Sponsored Trial Activity.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Medtech Insight: 世界の医療機器・医療技術の最新情報
A new template from the US FDA explains what information the agency wants to see in regulating COVID-19 tests to be performed outside the laboratory environment.
Topic Coronavirus FDA Diagnostics
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Pharma consulting: 医療用医薬品の...
Catch up on any missed COVID-19 24 hour webinar sessions
Topic Cardiovascular Coronavirus
Meddevicetracker: 医療機器の市場調査分析・データベース
Keep your finger on the pulse of digital health technologies with Meddevicetracker’s “Digital Health: Diabetes Apps and Virtual Coaching” report. An extract of this market analysis, covering smartphone apps, continuous glucose monitoring devices, and virtual diabetes coaching, is now available.
Topic digital-health diabetes
Medtech Insight: 世界の医療機器・医療技術の最新情報
The American Diabetes Association held their annual meeting virtually from June 12-16, 2020. Catch up with critical event updates and the latest developments, groundbreaking research and scientific advances from the editors and analysts at Medtech Insight, who were covering the event live and reporting on the vital medtech news and science to come out of the 80th Scientific Sessions.
Topic Diabetes
Citeline, Datamonitor Healthcare: 医療用医薬品の市場調査レポート
This web event has now ended. You will be able to watch all sessions on demand soon. Register your interest now to receive an update when all sessions are available to view.
Topic Coronavirus
With the COVID-19 pandemic raging, verified HCPs are turning to Skipta more than ever to access clinically relevant information reaching beyond the crisis. Find out how other brand managers engaged these members using Skipta’s disease-specific micro-communities.
Pink Sheet: 世界の薬事規制と承認審査に関するニュース
Considerations for switching from in-person to remote collection of patient- and observer-reported outcomes addressed in latest update to Q&A guidance, which also discusses Part 11 compliance requirements in the context of the pandemic and electronic collection of informed consent through MyStudies app.
Topic Coronavirus clinical-trials
Generics Bulletin: ジェネリック＆バイオシミラーニュース
A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.
Topic Coronavirus Distribution
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Topic Coronavirus
Generics Bulletin: ジェネリック＆バイオシミラーニュース
In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.
Topic Coronavirus Intellectual Property policy-and-regulation
製品説明＆デモお申込
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
＊一部のサービスでは無料トライアルをご利用になれません。
お問い合わせ先
ご質問等ございましたらお気軽にご連絡下さい。
日本（平日：9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。